Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians

Li, J; Yang, J; Kong, LF; Huang, YJ; Chen, P; Yan, XX; Liu, XX; Zho, XDG; Liu, JM; Zhu, XL; Humphries, M; Wang, LD; Pethe, A; Wang, XT; Kottakis, I; Fogel, R; Zhong, NS

Zhong, NS (通讯作者)，Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.

ASIAN PACIFIC JOURNAL OF ALLERGY AND IMMUNOLOGY, 2022; 40 (3): 223

Abstract

Background: Omalizumab has > 15 years of real-world evidence of effectiveness in Caucasian patients. In August 2017, it was approved as an add-on t......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索